Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia December 24, 2025 8:00 AM EST
Company Participants
Morgan Sanford – Vice President of Investor Relations
Brian Goff – CEO & Director
Sarah Gheuens – Chief Medical Officer and Head of Research & Development
Tsveta Milanova – Chief Commercial Officer
Cecilia Jones – Chief Financial Officer
Conference Call Participants
Samantha Semenkow – Citigroup Inc., Research Division
Gregory Renza – Truist Securities, Inc., Research Division
Eric Schmidt – Cantor Fitzgerald & Co., Research Division
Alec Stranahan – BofA Securities, Research Division
Marc Frahm – TD Cowen, Research Division
Emily Bodnar – H.C. Wainwright & Co, LLC, Research Division
Jiayi Yuan – RBC Capital Markets, Research Division
Presentation
Operator
Good day, and welcome to Agios Pharmaceuticals’ Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios’ request. I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at Agios.
Morgan Sanford
Vice President of Investor Relations
Thank you, operator. Good morning, everyone. Thank you for joining us to discuss the FDA approval of mitapivat for the treatment of anemia in adults with alpha or beta thalassemia which will be marketed under the brand name AQVESME in the United States. You can access the slides for today’s call by going to the Investors section of our website, agios.com. Next slide, please. Please note, we’ll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements due to various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
On the next slide, you’ll find the agenda for today’s call. On the call with
